iBio, Inc. (NASDAQ:IBIO) Short Interest Up 100.6% in December

iBio, Inc. (NASDAQ:IBIO) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 3,906,126 shares, an increase of 100.6% from the November 30th total of 1,947,486 shares. Approximately 17.9% of the company’s stock are sold short. Based on an average daily volume of 22,914,016 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 22,914,016 shares, the short-interest ratio is presently 0.2 days. Approximately 17.9% of the company’s stock are sold short.

iBio Trading Up 1.1%

NASDAQ:IBIO traded up $0.02 on Friday, hitting $1.89. The stock had a trading volume of 891,405 shares, compared to its average volume of 13,432,008. The business has a 50-day moving average price of $1.48. The stock has a market cap of $42.50 million, a PE ratio of -1.36 and a beta of 1.13. iBio has a 52-week low of $0.56 and a 52-week high of $6.89.

iBio (NASDAQ:IBIO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The firm had revenue of $0.10 million for the quarter.

Wall Street Analyst Weigh In

Several research firms recently commented on IBIO. Lifesci Capital raised iBio to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iBio in a report on Monday, December 22nd. Leerink Partnrs upgraded shares of iBio to a “strong-buy” rating in a research note on Friday, October 17th. Finally, Wall Street Zen raised shares of iBio from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, iBio has an average rating of “Buy”.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.